LXRX
Lexicon Pharmaceuticals Inc operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease. The company mainly designs and develops drugs for therapeutic areas.
Lexicon Pharmaceuticals, Inc. (LXRX) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Growth (D-). The rating has held at C for 13 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B- (2.9) | D- (0.9) | B (3.4) | C- (2.0) | C+ (2.6) | C (2.4) |
| 2026-11-06 | B- (2.9) | F (0.6) | B (3.4) | C (2.5) | C+ (2.7) | C (2.4) |
| 2026-10-30 | B- (2.9) | F (0.6) | B (3.4) | C+ (2.6) | C+ (2.7) | C (2.4) |
| 2026-10-23 | B- (2.9) | F (0.6) | B (3.3) | C+ (2.7) | C+ (2.6) | C (2.4) |
| 2026-10-16 | B- (2.9) | F (0.6) | B (3.3) | C (2.4) | C+ (2.6) | C (2.4) |